Algernon Pharmaceuticals Inc (AGNPF)

[lk52q]

GM evil. What this allows the company to achieve is the means to get treatments to the “finish line” potentially sooner than a novel type of treatment. The repurposed compounds typically have a lower risk of failing in human trials as a result of safety issues. It’s also a more capital efficient model as the science behind new therapies can cost hundreds of millions of dollars in many cases. $AGNPF

https://finance.yahoo.com/news/algernon-receives-regulatory-ethics-approval-113010577.html